Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort

Bossi, Paolo; Trama, Annalisa; Bernasconi, Alice; Grisanti, Salvatore; Mohamad, Issa; Galiana, I. Linares; Özyar, Enis; Franco, Pierfrancesco; Vecchio, Stefania; Bonomo, Pierluigi; Cirauqui, Beatriz; El-Sherify, Mustafa; Ursino, Stefano; Argiris, Athanassios; Pan, Jingbo; Wittekindt, Claus; D’Angelo, Elisa; Costa, Loredana; Buglione, Michela; Johnson, Jennifer M.; Airoldi, Mario; Mesı́a, Ricard; Resteghini, Carlo; Licitra, Lisa; Orlandi, Ester; Martín, Martín; Battaglia, Paolo; Turri‐Zanoni, Mario; Lionello, Marco; Azzarello, Giuseppe; Boscolo, Giorgia; Moro, Cecilia; Maffioletti, L.; Iannacone, Eva; Garassino, I.; Jong, Robert J. Baatenburg de; Hardillo, José A.; Mastromauro, Cataldo; Menazza, Sara; Secondino, Simona; Montagnani, Biella F.; Zustovich, Fable; Corte, Donatella Da; Renzi, Filippo De; Aprile, Giuseppe; Pancheri, Francesca; Rossetto, C.; Ghiani, M.; Carta, Paolo; Dessì, Andrea; Cau, Maria Chiara; Ramos, Silva; Charoula, Harilena; Giannakopoulou, Eleni; Verstraete, Hilde; Nevens, Daan; Velasco, Montse; Bonfill, Teresa; Restoy, E. Mur; Franzetti-Pellanda, Alessandra

doi:10.1016/j.ejca.2021.09.005

Cited by 13 publications

(22 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The keratinizing NPC subtype is more common in EBV-negative NPC than in EBV-positive NPC. Compared with EBV-negative patients, most NPC patients had nonkeratinizing tissue, which was more common in EBER (+) tumors (91% vs. 70%) [13]. Our study also con rmed this nding (98.6% vs. 81.3%).…”

Section: Discussionsupporting

confidence: 83%

Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation

Xiong

Yuan

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Because the vast majority of nasopharyngeal carcinoma (NPC) in Chinese patients is a direct result of Epstein–Barr virus (EBV) infection, there is a dearth of data for EBV-negative patients in this population. This multicenter study sought to examine the clinical characteristics of this population and compare long-term outcomes with a propensity-matched (1:1.5) EBV-positive cohort. Methods NPC patients with known EBV status from four hospitals were collated (2013–2021). A logistic regression model was conducted to evaluate the relationship between patient characteristics and EBV status. The Kaplan–Meier method and Cox regression analysis were used to analyze survival data. Results This study analyzed 48 (40%) EBV-negative and 72(60%)EBV-positive patients. The median follow-up time was 63.5 months. Most EBV-negative NPC patients (77.1%) were diagnosed in the advanced stages, and no significant prognostic factors were discerned in this subpopulation. EBV-negative disease was more associated with the keratinizing subtype (18.8% vs. 1.4%, P < 0.05), whereas nearly all EBV-positive cases were non-keratinizing. Compared to EBV-negative NPC patients, EBV-positive NPC patients were more likely to develop local recurrence (9.7% vs. 0%, P = 0.026). There was no statistical difference in mortality (8.3% vs. 4.2%, P = 0.34) during the follow-up period. Conclusions These multicenter data suggest that in the Chinese population, EBV-negative disease have similar survival outcomes as EBV-positive cases, despite the increased local recurrence in the latter. Further work is required to corroborate these conclusions. Trial registration: retrospectively registered (Permit Number: LLHBCH2022YN-037). This retrospective study followed the principles of the Helsinki Declaration and was approved by the Ethics Committee of Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.

show abstract

Section: Discussionsupporting

confidence: 83%

Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation

Xiong

Yuan

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The patients with nasopharyngeal carcinoma do not have specific symptoms in the early stage. Therefore, when the patients are diagnosed as the cases with nasopharyngeal carcinoma, they are often in the middle or late stage with the 5-year survival rate of under 15.0%, and 70.0% of them have metastasis [ 15 ]. The general survival status of the patients is not optimistic.…”

Section: Discussionmentioning

confidence: 99%

Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors

Feng

Luo

Cao

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Objective. To investigate the effects of CIK (cytokine-induced killer) cell therapy combined with camrelizumab on the quality of life in patients with nasopharyngeal carcinoma and prognostic factors. Methods. In this retrospective study, the materials of 80 patients with nasopharyngeal carcinoma treated in our hospital (February 2017–February 2019) were retrospectively analyzed, and they were equalized into experimental group (n = 40) and control group (n = 40) according to the order of admission. Both groups received 200 mg of camrelizumab on day 1 combined with 10 mg of anrotinib from day 2 to day 4. The patients received the above program every 3 weeks and 4 treatment cycles. The experimental group also received CIK cell therapy simultaneously. The patients’ quality of life, immune indexes, local control, metastasis, and survival rate were compared between the two groups, and the prognostic factors were analyzed by logistic analysis. Results. Compared with the control group, the experimental group achieved much higher scores of physical well-being (18.38 ± 2.31), social/family well-being (16.40 ± 2.24), emotional well-being (15.35 ± 2.30), functional well-being (17.30 ± 2.20), and head and neck cancer subscale (15.40 ± 2.01, P < 0.001) and eminently better immune indexes ( P < 0.001) after treatment. During the 24-month follow-up, there were 2 recurrent cases (5.0%) and 2 cases (5.0%) with distant metastasis among the 40 patients in the experimental group; there were 8 recurrent cases (20.0%) and 7 cases (17.5%) with distant metastasis among the 40 patients in the control group. In the experimental group, the median survival period was 18 months and the 2-year survival rate was 97.5% (39/40). In the control group, the median survival period was 14 months and the 2-year survival rate was 85.0% (34/40). Among the 80 patients, 7 cases (8.75%) died and 73 cases (91.25%) survived. After conducting the single-factor analysis, remarkable differences in the cases of IV stage, quality of life after treatment, and immune indexes after treatment between the survival group and the death group were observed ( P < 0.05). According to the multiple-factor analysis, the clinical stage and immune indexes were identified as the prognostic factors. Conclusion. CIK cell therapy combined with camrelizumab can enhance the life quality and immune function of the patients with nasopharyngeal carcinoma, thus improving their prognoses.

show abstract

“…However, the effect of radiotherapy alone was not inferior to concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma [12]. In an international multicenter retrospective study [13], patients with NPC diagnosed between 2004 and 2017 in 36 hospitals in 11 countries were analyzed. The treatments these patients received were divided into nonintensive treatment (NIT), including simple twodimensional radiotherapy (RT), three-dimensional conformal radiotherapy (3D-CRT) or intensitymodulated radiation therapy (IMRT), and intensive treatment (IT), including concurrent chemoradiotherapy (CCRT) combined with induction or adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation

Xiong

Yuan

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Because the vast majority of nasopharyngeal carcinoma (NPC) in Chinese patients is a direct result of Epstein–Barr virus (EBV) infection, there is a dearth of data for EBV-negative patients in this population. This multicenter study sought to examine the clinical characteristics of this population and compare long-term outcomes with a propensity-matched (1:1.5) EBV-positive cohort. Methods: NPC patients with known EBV status from four hospitals were collated (2013-2021). A logisticregression model was conducted to evaluate the relationship between patient characteristics and EBV status. The Kaplan–Meier method and Coxregression analysis were used to analyze survival data. Results: This study analyzed 48 (40%) EBV-negative and 72（60%）EBV-positive patients. The median follow-up time was 63.5 months. Most EBV-negative NPC patients (77.1%) were diagnosed in the advanced stages, and no significant prognostic factors were discerned in this subpopulation. EBV-negative disease was more associated with the keratinizing subtype (18.8% vs. 1.4%, P<0.05), whereas nearly all EBV-positive cases were non-keratinizing. Compared to EBV-negative NPC patients, EBV-positive NPC patients were more likely to develop local recurrence (9.7% vs. 0%, P=0.026). There was no statistical difference in mortality (8.3% vs. 4.2%, P=0.34) during the follow-up period. Conclusions: These multicenter data suggest that in the Chinese population, EBV-negative disease have similar survival outcomes as EBV-positive cases, despite the increased local recurrence in the latter. Further work is required to corroborate these conclusions. Trial registration: retrospectively registered (Permit Number: LLHBCH2022YN-037). This retrospective study followed the principles of the Helsinki Declaration and was approved by the Ethics Committee of Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.

show abstract

Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort

Cited by 13 publications

References 28 publications

Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation

Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation

Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors

Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation

Contact Info

Product

Resources

About